Tvardi Therapeutics, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Imran Alibhai
- Full Time Employees
- 12
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3 Sugar Creek Center Boulevard Sugar Land TX United States of America 77478
- IPO Date
- Jan 31, 2014
- CIK
- 0001346830
- Website
- tvarditherapeutics.com
- Similar Companies
- Business
- Tvardi Therapeutics, Inc. (Nasdaq: TVRD) is a clinical-stage biopharmaceutical company that develops novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need, including idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC). The company's lead product candidate, TTI-101, an oral small molecule STAT3 inhibitor that binds to the SH2 domain to block pY-STAT3 phosphorylation, dimerization, and nuclear translocation while preserving non-canonical mitochondrial functions, advances in Phase 2 clinical trials for IPF (REVERT-IPF trial, NCT05671835, topline data expected Q4 2025) and HCC (NCT05440708, topline data expected H1 2026), with FDA orphan drug and Fast Track designations; its second candidate, TTI-109, a structurally related yet distinct oral STAT3 inhibitor with demonstrated tolerability, bioavailability, and potency, completed IND-enabling studies and received an IND submission to the FDA in June 2025. Founded in 2017 and headquartered in Sugar Land, Texas, Tvardi operates primarily in the United States with a focus on high-unmet-need fibrotic and oncologic indications driven by STAT3-mediated inflammation, proliferation, extracellular matrix deposition, and immune suppression. In April 2025, Tvardi completed its merger with Cara Therapeutics, Inc., acquiring approximately $24 million in net cash to bolster its balance sheet alongside a $28.3 million private placement financing from new and existing institutional investors in December 2024, providing runway into the second half of 2026 through anticipated Phase 2 readouts; the company also completed enrollment in the REVERT-IPF Phase 2 trial and presented supporting data at the American Thoracic Society 2025 Conference.
TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript
Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
Tvardi Therapeutics to Participate in Upcoming Investor Events
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
Brokerages Set Tvardi Therapeutics, Inc. (NASDAQ:TVRD) PT at $55.50
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Average PT from Analysts
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
SHAREHOLDER INVESTOR REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
TVRD INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics